Compare Abbott Laboratories (ABT) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Diamondback Energy Inc — how do they compare? Abbott Laboratories trades at $95.44 (market cap $166.94B), while Diamondback Energy Inc trades at $185.64 (market cap $50.79B). The key difference: Abbott Laboratories is far larger — about 3.3× Diamondback Energy Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | FANG | |
|---|---|---|
Market Cap | $166.94B | $50.79B |
Sector | Health | Energy |
52-Week High | $136.62 | $213.69 |
52-Week Low | $82.57 | $134.53 |
Enterprise Value | $193.69B | $64.52B |
Dividend Yield | 2.63% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Diamondback Energy (FANG) trades at $180.56, up 4.95% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth to $14.93B in 2025 but faces declining net margins. Analyst consensus is overwhelmingly bullish with a $232.10 price target, supported by positive energy sector sentiment from Zacks and Seeking Alpha as of late June 2026.
FANG offers upside potential from high analyst targets and operational cash flow strength, but risks include volatile oil prices, margin compression, and technical resistance near $175. The stock's high P/E of 177.28 reflects growth expectations, yet execution on Q2 2026 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
